To date, ONL has raised nearly $15 million through a combination of traditional financing efforts and securing of research grants.

In prior financing, the company completed a $4.25 million Series A financing round that involved both existing and new investors including Novartis, the University of Michigan’s Michigan Investment in New Technology Startups (MINTS) program, Capital Community Angels, Invest Michigan, Biosciences Research & Commercialization Center and Hestia Investments.

Most recently, the company completed a $3 million convertible note financing. Participation in the financing was a balance of current investors, ONL management, and new investors. The largest new investor in the company is InFocus Capital Partners, a leading venture capital firm focused on unique investments in the ophthalmology market.

The proceeds from the convertible note financing, combined with a recent grant from the National Eye Institute, enables ONL to complete an ongoing Phase I clinical study in retinal detachment and perform activities to enable chronic indications with significant unmet needs.

To find out more about investing in ONL Therapeutics, please contact us at:

ONL Therapeutics
1600 Huron Pkwy
Building 520, Second Floor
Ann Arbor, MI 48109
info@onltherapeutics.com

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt

Start typing and press Enter to search